{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T22:55:56Z","timestamp":1771455356314,"version":"3.50.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2587,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1002\/hep.22321","type":"journal-article","created":{"date-parts":[[2008,3,18]],"date-time":"2008-03-18T18:47:37Z","timestamp":1205866057000},"page":"398-406","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":88,"title":["Robust antiviral activity of R1626, a novel nucleoside analog"],"prefix":"10.1097","volume":"48","author":[{"given":"Stuart K.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Cooksley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Robson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Berns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Klumpp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Najera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Washington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20241201","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa\u20102a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R2-8-20241201","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa\u20102b plus ribavirin compared with interferon alfa\u20102b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R3-8-20241201","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa\u20102a plus ribavirin for chronic hepatitis C virus infection in HIV\u2010infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-8-20241201","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa\u20102a plus ribavirin versus interferon alfa\u20102a plus ribavirin for chronic hepatitis C in HIV\u2010coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"R5-8-20241201","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMp048068","article-title":"Treating hepatitis C in \u201cdifficult\u2010to\u2010treat\u201d patients","volume":"351","author":"Pawlotsky","year":"2004","journal-title":"N Engl J Med"},{"key":"R6-8-20241201","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1074\/jbc.M510195200","article-title":"The novel nucleoside analogue R1479 (4\u2032\u2010azidocytidine) is a potent inhibitor of NS5B\u2010dependent RNA synthesis and hepatitis C virus replication in cell culture","volume":"281","author":"Klumpp","year":"2006","journal-title":"J Biol Chem"},{"key":"R7-8-20241201","first-page":"S98","article-title":"Safety, tolerability and pharmacokinetics of R1626, a novel nucleoside analog targeting HCV polymerase: results from a phase 1 single dose escalation trial in healthy subjects","volume":"81","author":"Robson","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R9-8-20241201","first-page":"S228","article-title":"R1479, a novel nucleoside analog and potent inhibitor of HCV replication, does not affect ribavirin\u2010induced hemolysis and erythrocyte fragility in vitro","volume":"46","author":"Jiang","year":"2007","journal-title":"J Hepatol"},{"key":"R10-8-20241201","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-8278(04)90096-7","article-title":"First clinical results for a novel antiviral treatment for hepatitis C: a phase I\/II dose escalation trial assessing tolerance, pharmacokinetics and antiviral activity of NM283","volume":"40","author":"Godofsky","year":"2004","journal-title":"J Hepatol"},{"key":"R11-8-20241201","first-page":"726A","article-title":"Final phase I\/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV\u20101 infection, including previous interferon failures","volume":"40","author":"Afdhal","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R12-8-20241201","first-page":"A1","article-title":"Antiviral activity of the non\u2010nucleoside polymerase inhibitor, HCV\u2010796, in patients with chronic hepatitis C virus: preliminary results from a randomized, double\u2010blind, placebo\u2010controlled, ascending multiple dose study","volume":"130","author":"Chandra","year":"2006","journal-title":"Gastroenterology"},{"key":"R13-8-20241201","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.virol.2006.03.045","article-title":"In vitro selected Con1 subgenomic replicons resistant to 2\u2032\u2010C\u2010methyl\u2010cytidine or to R1479 show lack of cross resistance","volume":"351","author":"Le Pogam","year":"2006","journal-title":"Virology"},{"key":"R14-8-20241201","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","article-title":"Rapid decline of viral RNA in hepatitis C patients treated with VX\u2010950: a phase Ib, placebo\u2010controlled, randomized study","volume":"131","author":"Reesink","year":"2006","journal-title":"Gastroenterology"},{"key":"R15-8-20241201","first-page":"607A","article-title":"Analysis of HCV NS5B genetic variants following monotherapy with HCV\u2010796, a non\u2010nucleoside polymerase inhibitor, in treatment naive HCV\u2010infected patients","volume":"44","author":"Villano","year":"2006","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22321","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200808000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:18:26Z","timestamp":1733059106000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200808000-00008"}},"subtitle":["A randomized, placebo\u2010controlled study in patients with chronic hepatitis C\u2020"],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22321","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}